Optiflow™
Flow Matters

Keeping you up-to-date with emerging nasal high flow (NHF) clinical evidence and practice guidelines. 


Take me to the latest edition
Evidence is published weekly demonstrating the impact of NHF on improved patient care and outcomes.
More than 400 studies have been published in the first half of 2022. 
Publications by year
(updated June 2022)

pubmed.com - search term 'nasal high flow'
Registered clinical trials
(updated June 2022)

clinicaltrials.gov - search term 'nasal high flow'
Decades of research is being used to inform
clinical practice guidelines
 
 
Flow Matters COVID-19 updated Feb 2022
 

Evidence-based guidelines recommend the use of NHF for COVID-19 patients

New study finding

Among patients with severe COVID-19, use of [NHF]  decreased the need for mechanical ventilation, 
compared with conventional low-flow oxygen therapy.

Read the updated edition now

 

NHF therapy in pediatric care

The use of NHF as a primary treatment for infants with bronchiolitis in the ED resulted in a significantly lower rate of therapy failure compared with standard oxygen therapy.
1 in 9 patients experienced therapy failure on
NHF 2 L/kg/min
1 in 4 patients experienced therapy failure on
standard O2 < 2 L/min


Latest Flow Matters Edition

Early use of NHF in infants and children

In our latest edition of Flow Matters, we review the literature and provide an evidence-based approach to implementation of NHF in pediatric patients.

Read online

Download PDF
 

Share

LinkedIn  Twitter

Clinical practice guideline recommendations

The Rochwerg et al. 2020. Intensive Care Med. clinical practice guideline synthesizes current best evidence into four recommendations for NHF in adult patients.

View this edition of Flow Matters
Acute hypoxemic respiratory failure


Acute hypoxemic
respiratory failure

For primary respiratory support compared to COT.
Recommendation made with moderate certainty.

Strong
Recommendation 

Post-operative

Post-operative
 
For primary respiratory support compared to COT in high risk and/or obese patients following cardiac or thoracic surgery.
Recommendation made with moderate certainty.
 
Conditional Recommendation 
Peri-intubation

Peri-intubation
 
For pre-oxygenation prior to in-ICU intubation no recommendation is made compared to COT.
NHF during intubation should be continued for patients who are already receiving NHF.*
 
Continue NHF* 

*For patients who are already receiving NHF, guideline authors suggest continuing NHF during intubation (conditional recommendation, moderate certainty).
Post-extubation

Post-extubation
respiratory failure
 
For post-extubation respiratory support compared to COT following extubation.
Recommendation made with moderate certainty.

Conditional Recommendation 


Clinical practice guidelines

In this edition of Flow Matters, we outline the recommendations, discuss the evidence-practice gap, and the economics of Nasal High Flow.

Read online

Download PDF
 

Share

LinkedIn  Twitter

Updated 9 Nov 2021
 

Evidence-based guidelines recommend the use of NHF for COVID-19 patients 

Read about this and research related to airborne transmission.

Read online


Download PDF

Share

LinkedIn  Twitter

ROX Index - a bedside tool for monitoring patients on NHF

The validated ROX index uses just 3 data points to provide an indicator of outcomes in adults with AHRF receiving NHF therapy.


Author: Stanislav Taktov, M.D., Ph.D.

Read online


Download PDF

Share

LinkedIn  Twitter

A survey - the NHF systems & settings used in published research

Surveys of the studies comprising the body of NHF evidence found the majority used F&P Optiflow NHF therapy systems and flow settings between 45 and 60 L/min.

Read online


Download PDF

Share

LinkedIn  Twitter

Subscribe to Flow Matters
If you would like to subscribe to our newsletter, please provide the following information so we can add you to our email list.
 


 


 


 
Enter security code:*
 Security code


 

 

By submitting this form, you consent to Fisher & Paykel Healthcare storing your personal information to contact you about your enquiry. Your information will be collected and stored securely by Fisher & Paykel Healthcare Limited based in New Zealand and may be shared with the wider Fisher & Paykel Healthcare group as necessary to support your enquiry. We will not share, disclose or sell your information to third parties for marketing purposes. For full details on how we use and manage your personal information, how long we may retain this information for sales or marketing purposes, your rights to access, correct or delete your personal information, and how to contact us about your personal information, please see our privacy statement.